Trispecific and/or trivalent binding proteins
US-10882922-B2 · Jan 5, 2021 · US
Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies
US11987644B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11987644-B2 |
| Application number | US-202016844999-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 9, 2020 |
| Priority date | Jun 12, 2017 |
| Publication date | May 21, 2024 |
| Grant date | May 21, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof, and methods of manufacturing such antibodies by co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines.
First claim
Opening claim text (preview).
The invention claimed is: 1. A bispecific antibody, wherein the bispecific antibody binds to IL-18 and IL-1β and comprises: a first immunoglobulin heavy chain comprising the amino acid sequence SEQ ID NO. 87; a first immunoglobulin light chain comprising the amino acid sequence SEQ ID NO. 103; a second immunoglobulin heavy chain comprising the amino acid sequence SEQ ID NO. 55; and a second immunoglobulin light chain comprising the amino acid sequence SEQ ID No. 71. 2. A pharmaceutical composition comprising the bispecific antibody according to claim 1 and a pharmaceutically acceptable carrier. 3. A method of treating an inflammasome related disorder comprising administering to a subject afflicted with an inflammasome related disorder an effective amount of a bispecific antibody according to claim 1 . 4. The method of claim 3 , wherein the inflammasome related disorder is sickle cell disease, vasculopathy, ischemia-reperfusion injury, cardiovascular disease, peripheral artery disease, atherosclerosis, vascular dysfunction, skeletal muscle ischemia, pulmonary sarcoidosis, fibrosis, malaria, hemodialysis-dependent chronic kidney disease, or Crohn's disease.
Assignees
Inventors
Classifications
Constant or Fc region; Isotype · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
comprising antibodies · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11987644B2 cover?
- The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof, and methods of manufacturing such antibodies by co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines.
- Who is the assignee on this patent?
- Novartis Ag
- What technology area does this patent fall under?
- Primary CPC classification A61P1/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).